Actelion to take ponesimod into pivotal psoriasis studies, but MS can wait
This article was originally published in Scrip
Executive Summary
Actelion's chances of finding a partner for its selective sphingosine 1 phosphate receptor 1 agonist ponesimod have received a boost from positive Phase IIb data in a second indication, plaque psoriasis.